Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:54 pm Purchase |
2024-12-31 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
Armistice Capital, LLC | 46,716 9.990% |
46,716 (New Position) |
Filing History |
| 2025-01-28 4:44 pm Purchase |
2025-01-27 | 13D | Quoin Pharmaceuticals, Ltd. QNRX |
Michael Myers | 46,962 4.900% |
15,833 (+50.86%) |
Filing History |
| 2025-01-28 4:43 pm Purchase |
2025-01-27 | 13D | Quoin Pharmaceuticals, Ltd. QNRX |
Denise Carter | 46,962 4.900% |
15,841 (+50.90%) |
Filing History |
| 2025-01-02 5:20 pm Purchase |
2024-12-23 | 13D | Quoin Pharmaceuticals, Ltd. QNRX |
Denise Carter | 31,121 6.900% |
31,121 (New Position) |
Filing History |
| 2025-01-02 5:20 pm Purchase |
2024-12-23 | 13D | Quoin Pharmaceuticals, Ltd. QNRX |
Michael Myers | 31,129 6.900% |
31,129 (New Position) |
Filing History |
| 2024-11-14 7:23 pm Purchase |
2024-09-30 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
Lind Global Fund II LP | 3,125 1.200% |
3,125 (New Position) |
Filing History |
| 2024-02-13 8:11 pm Sale |
2023-12-31 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
Lind Global Fund II LP | 3,125 6.000% |
-1,000 (-24.24%) |
Filing History |
| 2023-03-03 4:18 pm Purchase |
2023-02-24 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
Lind Global Fund II LP | 4,125 9.900% |
4,125 (New Position) |
Filing History |
| 2023-02-14 2:40 pm Purchase |
2022-12-30 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
GOLDMAN SACHS GROUP INC GS |
0 0.000% |
0 (New Position) |
Filing History |
| 2023-02-14 11:25 am Sale |
2022-12-31 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
CVI Investments, Inc. | 5,303,073 4.900% |
-946,927 (-15.15%) |
Filing History |
| 2022-08-12 10:01 am Purchase |
2022-08-05 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
CVI Investments, Inc. | 6,250,000 8.200% |
6,250,000 (New Position) |
Filing History |
| 2022-03-10 3:26 pm Purchase |
2022-02-28 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
GOLDMAN SACHS GROUP INC GS |
484 17.400% |
227 (+88.16%) |
Filing History |
| 2022-02-14 3:06 pm Purchase |
2021-12-31 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
Altium Capital Management LLC | 1,425 4.990% |
1,013 (+245.30%) |
Filing History |
| 2022-02-10 4:32 pm Purchase |
2021-12-31 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
GOLDMAN SACHS GROUP INC GS |
257 9.200% |
257 (New Position) |
Filing History |
| 2021-11-12 2:20 pm Purchase |
2021-10-29 | 13G | Quoin Pharmaceuticals, Ltd. QNRX |
Altium Capital Management LLC | 413 9.990% |
413 (New Position) |
Filing History |
| 2021-02-16 09:42 am Sale |
2020-12-31 | 13G | CELLECT BIOTECHNOLOGY LTD SPON APOP |
CVI Investments, Inc. | 0 0.000% |
-30,500,000 (Position Closed) |
Filing History |
| 2021-01-13 09:03 am Sale |
2020-12-31 | 13G | CELLECT BIOTECHNOLOGY LTD SPON APOP |
Empery Asset Management, LP | 185,200 0.050% |
-32,114,800 (-99.43%) |
Filing History |